Product
Turoctocog alfa pegol
Aliases
turoctocog alfa pegol (N8-GP), Turoctocog alfa pegol (N8-GP)
5 clinical trials
2 indications
Indication
Hemophilia AIndication
Congenital Bleeding DisorderClinical trial
A Multinational, Prospective, Open Labelled, Non-controlled, Non-interventional Post-authorisation Study of Turoctocog Alfa Pegol (N8-GP) During Long-term Routine Prophylaxis and Treatment of Bleeding Episodes in Patients With Haemophilia AStatus: , Estimated PCD: 2027-06-03
Clinical trial
A Multi-centre, Open-label Trial Evaluating Efficacy, Safety and Pharmacokinetics of Turoctocog Alfa Pegol (N8-GP) When Used for Treatment and Prophylaxis of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia AStatus: Completed, Estimated PCD: 2022-12-28
Clinical trial
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolStatus: , Estimated PCD: 2025-04-01
Clinical trial
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia AStatus: Completed, Estimated PCD: 2020-12-03
Clinical trial
Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®. A Multi-centre, Prospective, Observational, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Effectiveness of Esperoct® in Haemophilia A Patients Under Routine Clinical Practice Conditions in JapanStatus: , Estimated PCD: 2025-02-28